谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Momelotinib Versus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis: an Efficacy/safety Analysis in the Japanese Subgroup of the Phase 3 Randomized SIMPLIFY-1 Trial.

Kazuya Shimoda,Norio Komatsu,Itaru Matsumura,Kazuhiko Ikeda,Masayuki Hino,Michihiro Hidaka,Yoshinobu Maeda,Takeshi Kondo,Tomoaki Fujisaki, Keita Shoshi, Kyoichi Azuma, Ryuichi Fukushima,Jun Kawashima,Hiroshi Kosugi

International Journal of Hematology（2024）

引用 0|浏览2
关键词
Momelotinib,Phase 3,Myelofibrosis,Ruxolitinib,Japan
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要